Lars Arvastson

1 presentation

• W26. POOLED INDIVIDUAL PATIENT DATA ANALYSIS OF THREE PHASE 2 TRIALS SUPPORTS VASOPRESSIN V1B RECEPTOR ANTAGONISM (BH-200 250 MG BID) AS AN ANTIDEPRESSANT MECHANISM FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

  2026 ASCP Annual Meeting